凯捷（Capgemini）：2025肿瘤患者体验未来图景展望报告（英文版）（16页）.pdf

《凯捷（Capgemini）：2025肿瘤患者体验未来图景展望报告（英文版）（16页）.pdf》由会员分享，可在线阅读，更多相关《凯捷（Capgemini）：2025肿瘤患者体验未来图景展望报告（英文版）（16页）.pdf（16页珍藏版）》请在三个皮匠报告上搜索。

1、Envisioning the Future of Oncology Patient ExperienceA Capgemini point of view2Envisioning the Future of OncologyThe field is shifting from one-size-fits-all treatments like traditional chemotherapy to precision therapies tailored to a patients unique genetic profile.At the same time,cancer diagnosi

2、s is moving from reactive,late-stage detection based on symptoms to proactive,AI-driven early detection through advanced imaging,blood tests,and risk profiling often identifying cancer before symptoms appear.In parallel,cancer vaccines are reshaping oncology by training the immune system to target p

3、atient specific tumour antigens,with the primary goal of preventing recurrence.This evolution promises not only better outcomes but also fewer side effects and a more human experience.Todays patients are no longer passive recipients of care.They demand to be informed and empowered,and expect to be a

4、ctive participants in their treatment.This shift brings new demands upon Pharma,MedTech and BioTech companies,and front-line healthcare:for clarity in communication,seamless support across the care continuum,and technology that enhances not complicates the patients experience.Technology that boosts

5、human-to-human interaction during diagnosis and provides meaningful support to patients as they process important health information especially when no one else is physically present helping them feel guided and cared for throughout their journey.Pharma companies are responding to these demands by e

6、xpanding their role beyond the molecule.Increasingly,were seeing wraparound services come into the fore-supporting patient access(including pricing),symptom management,and emotional wellbeing.And with the rise of AI and Customer Relationship Management(CRM)transformations,healthcare providers can no